Characteristic | Young group | Old group | P value |
---|---|---|---|
Age at ablation time (years) | 31.6 ± 4.2 (20–35) | 49 ± 8.4 (36–66) | < 0.001 |
Gender | 0.85 | ||
Male | 23 (76.6 %) | 34 (73.9%) | |
Female | 7 (23.3%) | 12 (26.1%) | |
BMI (kg/m2) | 27 ± 3.7 | 29.2 ± 4.1 | 0.019 |
BMI > 25 kg/m2 | 10 (33.3%) | 18 (39.1%) | |
BMI > 30 kg/m2 | 8 (26.6%) | 21 (45.7%) | |
Arterial hypertension | 15 (50%) | 28 (60.9%) | 0.43 |
Diabetes mellitus | 5 (16.6%) | 10 (21.7%) | 0.63 |
Smoking | 5 (16.6%) | 14 (30.4%) | 0.201 |
Thyroid disease | 0 | 0 | |
Structural heart disease | 1 (3.3%) | 5 (10.8%) | 0.154 |
IHD | 0 | 4 | |
DCM | 0 | 0 | |
HCM | 1 | 1 | |
VHD | 0 | 0 | |
AF | |||
Duration (months) | 36 (12–120) | 36 (6–120) | 0.3 |
Frequency/month | 4 (2–6) | 3 (1–6) | 0.34 |
EHRA score | 3 (27 patients) | 3 (38 patients) | 0.29 |
LA volume (ml) | 39.6 ± 3.1 | 52.8 ± 4.9 | 0.001 |
LVEF% | 65.6 ± 3.2 | 64.2 ± 4.5 | 0.138 |
CHA2DS2-VASc score | 0.93 ± 0.75 | 2.11 ± 1.32 | < 0.001 |
Median 1 | Median 2 | ||
Beta blockers | 2 (6.7%) | 4 (8.7%) | |
Class I AAD | 16 (53.3%) | 20 (43.5%) | |
Class III AAD | 12 (40%) | 26 (56.5%) |